Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through two segments: Proteomics and Genomics. It provides SomaScan platform that enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanism; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system redefines high-throughput genomics by delivering exceptional efficiency, precision, and scalability for qPCR applications. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Inc.

Wells Fargo analyst Brandon Couillard maintained a Hold rating on Mesa Laboratories today and set a price target of $110.00. Couillard covers the H...

Mesa Laboratories (MLAB) Receives a Hold from Wells Fargo

MediPharm Labs ( ($TSE:LABS) ) has issued an update. MediPharm Labs has scheduled the release of its second-quarter 2026 financial results for Augu...

MediPharm Labs Sets Date for Q2 2026 Results Amid Global Medical Cannabis Expansion

In a report released yesterday, from CICC maintained a Buy rating on Zai Lab Ltd, with a price target of HK$20.20. The word on The Street in genera...

CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)

Citi analyst maintained a Buy rating on Zai Lab Ltd on August 6 and set a price target of HK$35.10. The company’s shares closed last Thursday at HK...

Citi Sticks to Their Buy Rating for Zai Lab Ltd (1ZLB)

In a report released yesterday, from UBS maintained a Buy rating on Zai Lab Ltd, with a price target of HK$27.00. Currently, the analyst consensus ...

UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)

Standard BioTools ( ($LAB) ) has issued an announcement. Standard BioTools reported second-quarter 2026 revenue of $20.1 million, down 7.6% year-ov...

Standard BioTools Q2 Results Highlight Strategic Restructuring

Astera Labs, Inc. (ALAB) Receives a Rating Update from a Top Analyst

Roth MKM analyst Suji Desilva maintained a Buy rating on Astera Labs, Inc. yesterday and set a price target of $450.00. According to TipRanks, Desi...

Astera Labs, Inc. (ALAB) Receives a Buy from Roth MKM

Jefferies analyst Blayne Curtis maintained a Buy rating on Astera Labs, Inc. yesterday and set a price target of $450.00. According to TipRanks, Cu...

Astera Labs, Inc. (ALAB): New Buy Recommendation for This Technology Giant

Analysts have been eager to weigh in on the Technology sector with new ratings on Astera Labs, Inc. (ALAB), Monolithic Power (MPWR) and Apple (AAPL...

Analysts’ Opinions Are Mixed on These Technology Stocks: Astera Labs, Inc. (ALAB), Monolithic Power (MPWR) and Apple (AAPL)

In a report released today, Papa Talla Sylla from Citi maintained a Buy rating on Astera Labs, Inc., with a price target of $315.00. According to T...

New Buy Rating for Astera Labs, Inc. (ALAB), the Technology Giant

In a report released on July 27, from UBS maintained a Buy rating on Zai Lab Ltd, with a price target of HK$27.00. The company’s shares closed last...

Standard BioTools ( ($LAB) ) has issued an update. On July 24, 2026, Standard BioTools agreed a termination and waiver deal with Illumina under whi...

Standard BioTools Divests Mass Cytometry to Multiplex Bio

Standard BioTools ( ($LAB) ) has shared an update. On July 22, 2026, Standard BioTools disclosed that it had received a notice from Nasdaq stating ...

Standard BioTools Receives Nasdaq Bid Price Deficiency Notice

Genomma Lab Internacional SAB de CV Class B (($MX:LABB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genomma Lab In...

Genomma Lab Earnings Call Balances Pressure and Recovery

Lakewood-Amedex Biotherapeutics stock soared after the company reported that Nu-3 showed a high barrier to resistance in lab tests.


Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up Today?

The share price has nearly doubled this year. 


	A	B	C	D
1	Symbol	Price	Change	Volume
2	LAB	$0.69	-3.07%	1.35M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LAB	$0.69	-3.1%	1.35M
3
4
5
6

LAB

Get Standard BioTools Inc. Data in Excel

Get Standard BioTools Inc. Data in Excel